KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Consolidated Net Income (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Consolidated Net Income data on record, last reported at $153.6 million in Q2 2025.

  • For Q2 2025, Consolidated Net Income rose 2272.05% year-over-year to $153.6 million; the TTM value through Dec 2025 reached $153.6 million, up 7.53%, while the annual FY2024 figure was $142.9 million, 148.06% up from the prior year.
  • Consolidated Net Income reached $153.6 million in Q2 2025 per SRPT's latest filing, up from $66.7 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $329.3 million in Q4 2022 and bottomed at -$516.8 million in Q1 2023.
  • Average Consolidated Net Income over 5 years is -$40.3 million, with a median of -$40.9 million recorded in 2023.
  • Peak YoY movement for Consolidated Net Income: crashed 856.15% in 2021, then skyrocketed 2272.05% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at -$122.0 million in 2021, then skyrocketed by 369.99% to $329.3 million in 2022, then fell by 13.67% to $284.3 million in 2023, then tumbled by 76.56% to $66.7 million in 2024, then surged by 130.51% to $153.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Consolidated Net Income were $153.6 million in Q2 2025, $66.7 million in Q4 2024, and $33.6 million in Q3 2024.